3,603 Shares in Amgen Inc. $AMGN Purchased by Integrity Advisory Solutions LLC

Integrity Advisory Solutions LLC purchased a new stake in Amgen Inc. (NASDAQ:AMGN) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 3,603 shares of the medical research company’s stock, valued at approximately $1,017,000.

A number of other institutional investors also recently made changes to their positions in the company. West Family Investments Inc. boosted its holdings in Amgen by 1.1% in the 3rd quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock valued at $779,000 after purchasing an additional 30 shares during the period. Viawealth LLC lifted its stake in Amgen by 0.4% during the third quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock worth $2,023,000 after purchasing an additional 30 shares during the last quarter. TAGStone Capital Inc. boosted its holdings in shares of Amgen by 0.8% in the 3rd quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company’s stock valued at $1,157,000 after purchasing an additional 32 shares in the last quarter. BBR Partners LLC raised its holdings in shares of Amgen by 0.5% during the 3rd quarter. BBR Partners LLC now owns 7,117 shares of the medical research company’s stock worth $2,008,000 after buying an additional 32 shares in the last quarter. Finally, Nautilus Advisors LLC boosted its stake in Amgen by 1.5% in the third quarter. Nautilus Advisors LLC now owns 2,142 shares of the medical research company’s stock valued at $604,000 after buying an additional 32 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of AMGN opened at $367.60 on Friday. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The firm has a market capitalization of $198.16 billion, a P/E ratio of 25.83, a P/E/G ratio of 3.76 and a beta of 0.45. The stock has a 50 day moving average price of $352.53 and a two-hundred day moving average price of $321.90. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter in the prior year, the company earned $5.31 EPS. The business’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio is 70.84%.

Analyst Ratings Changes

Several brokerages recently commented on AMGN. Sanford C. Bernstein downgraded shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price objective for the company. in a research note on Tuesday, January 20th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research note on Thursday, February 5th. Citigroup increased their price objective on Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. Argus boosted their price target on shares of Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Finally, Barclays assumed coverage on shares of Amgen in a research note on Friday, February 20th. They set an “equal weight” rating and a $350.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amgen has an average rating of “Hold” and an average price target of $354.17.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Board approved a $2.52 quarterly dividend, payable June 5, 2026, supporting income investors and signaling cash-flow confidence. AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
• Positive Sentiment: Amgen launched a new Phase 3 subcutaneous trial to expand its blinatumomab franchise — a constructive pipeline development that could add long-term value if successful. Amgen Advances Blinatumomab Franchise With New Phase 3 Subcutaneous Trial
• Neutral Sentiment: Amgen will present at the Leerink Partners 2026 Global Healthcare Conference on March 11; management comments (CFO and SVP of rare disease) could offer incremental guidance or pipeline color. AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
• Neutral Sentiment: Coverage pieces examine post-earnings momentum and valuation (why AMGN has risen ~24% over the past year); useful for context but not single-driver news. Why Is Amgen (AMGN) Up 3.6% Since Last Earnings Report?
• Neutral Sentiment: Reported short-interest data in early March appears erroneous (0 shares / NaN change); treat as noise until reliable data is posted. (No link available)
• Negative Sentiment: Amgen and partner Kyowa Kirin halted all rocatinlimab trials after safety signals tying OX40 modulation to potential malignancies — this removes a late‑stage asset and raises near-term pipeline risk and uncertainty around R&D priorities. Amgen Faces Rocatinlimab Halt And Rethinks Pipeline And Capital Priorities
• Negative Sentiment: An analyst downgrade recommended waiting for a better entry point (rating cut / hold), which can amplify selling pressure after the pipeline news. Amgen: Wait For A Better Entry Point (Rating Downgrade)

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.